Is There a Best Drug for Overactive Bladder in a Patient with Dementia?
|
|
- Lucas Todd
- 6 years ago
- Views:
Transcription
1 Is There a Best Drug for Overactive Bladder in a Patient with Dementia? Todd Semla, MS, Pharm.D., BCPS, FCCP, AGSF National PBM Clinical Pharmacy Program Manager Mental Health & Geriatrics U.S. Department of Veterans Affairs Northwestern University Feinberg School of Medicine
2 Disclosures The views expressed are not necessarily those of the U.S. Department of Veterans Affairs or the U.S. Government Member of Omnicare, Inc. Pharmacy & Therapeutics Committee; Senior Editor, LexiComp, Inc; Member, AARP Caregiving Advisory Board Spouse an employee of AbbVie and owns stock in AbbVie, Abbott and Hospira.
3 The Clinical Conundrum 83 yo patient with Alzheimer s disease diagnosed 4 years ago; MMSE 18. Donepezil 10 mg daily. 23 year history of urinary incontinence, mixed type. Until recently managed with regular toileting and a pad. Recently, larger volumes lost, more frequently. Other problems: osteoarthritis managed with scheduled acetaminophen.
4 Dementia & OAB: Questions needing answers 1. Do anticholinergic agents developed to treat OAB improve continence in patients with dementia? 2. Do anticholinergic agents developed to treat OAB impair cognition in patients with dementia? 3. When part of the same regimen do anticholinergic agents negate the effects of acetylcholinesterase inhibitor on cognition? And vice versa? 4
5 Medications for OAB Generic name Oxybutynin chloride Oxybutynin chloride extended-release Oxybutynin chloride transdermal Oxybutynin gel Tolterodine tartrate Tolterodine tartrate extended-release Trospium chloride Trospium chloride ER Solifenacin succinate Darifenacin hydrobromide Fesoterodine fumarate Mirabegron Botulinum toxin Brand Ditropan Ditropan XL Oxytrol Gelnique Detrol Detrol LA Sanctura Sanctura XR Vesicare Enablex Toviaz Myrbetriq Various 5
6 What s the Evidence? Clinical report Chemical-physical properties Laboratory Observational studies Controlled trials
7 What Are the Consequences of Concurrent CI and Anticholinergic Use? Retrospective cohort study of AD patients stratified by anticholinergic use; all taking donepezil 10 mg QD Baseline MMSE: 22.6 ± 5.5 No anticholinergic use (n=53) 20.6 ± 4.0 Anticholinergic users (n=16) Change in MMSE Over Time 1 year 2 years No ACh ACh use No Ach Ach use n=53 p= n= n=25 p= n=11 Lu C & Tune LE Am J Geriatr Psychiatry 2003;11:
8 Muscarinic Receptor Subtypes: Location and Response Muscarinic Receptor Location Response M1 M2 M3 M4 Secretory glands, CNS, urethra, vascular smooth muscle Heart, respiratory tract, bladder, urethra, g.i. tract, uterus smooth muscle Smooth muscle and secretory glands; respiratory tract; bladder and the g.i. tract including salivary glands, eyes Smooth muscle and secretory glands; respiratory tract Smooth muscle contraction, gastric acid secretion, memory and learning Regulate heart rate and contractility; constipation Dry mouth, blurred vision Dry mouth M5 Ciliary muscle; eyes Dry mouth, blurred vision
9 Muscarinic Binding Affinities Agent Chemical amine M1 M2 M3 M4 M5 Uroselectivity Oxybutynin Tertiary amine M3>M2, min Tolterodine Tertiary amine None Trospium Quarternary amine None Darifenacin Tertiary amine M3 selective Solifenacin Tertiary amine Unkn Unkn M3>M2, min. FESO, 5HMT Tertiary amine Atropine Tertiary amine
10 Relative Lipophilicity Log P and dipole moment 1. Darifenacin 2. Oxybutynin, Solifenacin 3. Tolterodine 4. Trospium Most Least Log D:octanol-H 2 O: 1. Oxybutynin 2. Darifenacin 3. Tolterodine 4. Solifenacin 5. Fesoterodine 6. Trospium
11 P-glycoprotein Substrate? Darifenacin Fesoterodine (5-HMT) Trospium? Tolterodine (5-HMT)? Oxybutynin No - Solifenacin
12 Brain Anticholinergic Activity 5 drugs AA measured by radiolgand ( 3 H-QNB) binding to rat muscarinic receptors over range of known serum concentrations. Highest Intermediate Lowest 5-HMT, tolterodine > oxybutynin > darifenacin, solifenacin Darifenacin lowest AA over entire concentration range 5-HMT most extensive AA low to high concentration Tolterodine largest change in AA low to high (ratio 37.3) Solifenacin least change in AA low to high (ratio 1.37) Jakobsen, et al. JAGS 2011;59:501-5
13 Concurrent Use of Oxybutynin or Tolterodine and CI: Effect on cognition and function Prospective cohort, merged SSA and MDS databases (January 2003 December 2004) N = 3,536 NH residents: 44% >85 years old; 75% women 3,141 CI only 395 CI and Anticholinergic (196 oxy, 231 tolterodine) Median dual use: 141 days (77-262) Measure change in MDS ADL and MDS-COG 47% severe or complete ADL dependence >50% severe or very severe cognitive impairment Sink KM, et al. JAGS 2008
14 Sink, et al.: Results Change in ADL Function Highest functioning quartile at baseline CI alone: 1.08 vs. CI + anticholinergic: 1.62 Rate of ADL decline: change/quarter, p=.02 Change in Cognition No difference in rate of decline Oxybutynin vs. Tolterodine Rates of decline in ADLs and cognition did not differ or between IR and ER formulations Sink KM, et al. JAGS 2008
15 Cognitive, Behavioral and Physiological Changes in AD Patients as a Function of Incontinence Medications 9 patients with AD and urinary incontinence treated with oxybutynin or tolterodine 3 weeks on and off anticholinergic medication Cog. Assess. On ACh Off ACH p-value MMSE ADAS-cog Memory Behav. List No difference in NPI, ADLs, CG burden, Urinary frequency, or incontinence episodes. Significant inverse relationship between serum AA and MMSE. Jewart RD, et al. Am J Geriatr Psychiatry 2005;13:
16 CNS Effects of OAB Medications Darifenacin 3.75, 7.5, or 15 mg vs. placebo x 2 wks 1 No significant changes in memory, reaction time or word recognition sensitivity Alertness, calmness and contentment not affected Darifenacin 7.5, 15, or 20 mg vs. placebo x 7 days 2 27 healthy men, ages years No significant changes in cognitive function vs. placebo Oxybutynin, tolterodine, trospium vs. placebo 3,4 Quantitative EEG changes seen with oxybutynin 1 Lipton RB, et al. J Urol 2005; 173: Kay G, et al. BJU Int 2005;96: Todorva A, et al. J Clin Pharmacol 2001;41: Pietzko A, et al. Eur J Clin Pharmacol 1994;47:
17 Oxybutynin ER vs. Placebo in Cognitively Impaired Elderly with Urinary Incontinence 50 female NH residents with mild to severe cognitive impairment and urinary incontinence Randomized to 4-weeks oxybutynin ER 5 mg or placebo once daily; no additional behavioral treatments for UI Confusion Assessment Method, MMSE, Severe Impairment Battery, Brief Agitation Rating Scale No SD between treatments in UI episodes, frequency or dryness No decline in cognition; well tolerated Lackner TE, et al. JAGS 2008 and JAMDA
18 Solifenacin Single dose R, DB, PC, 3-way, X-over design Solifenacin 10 mg, oxybutynin IR 10mg 12 healthy adults >65; MMSE>27 Solifenacin Quality of Working Memory after 2 & 4 hours Oxybutynin after 6 hours significant impairment in attention, working memory, and self-rated alertness compared to placebo Wesnes, et al., Expert Opin Drug Safety 2009;8:
19 Solifenacin in Patients with MCI R, DB, PC Triple X-over trial 26 subjects >75 years with MCI per criteria including MMSE >23 Solifenacin 5 mg QD, oxybutynin 5 mg BID, and placebo x 21 days Neither solifenacin or oxybutynin significantly changed cognitive function from baseline. NS difference: solifenacin vs. placebo Decreased continuity of attention: oxybutynin vs. placebo 1 hour post dose. Wagg et al. Euro Urol 2013;64:74-81
20 Trospium Ho: Trospium should not penetrate the BBB and should not impair cognitive function. 12 healthy subjects; years old; MMSE>25 Trospium ER 60 mg daily for 10 days Hopkins Verbal Learning Test-Revised and Brief Visuospatial Memory Test-Revised at baseline, Days 0 and 10. CSF trospium concentrations Day 10 at 0,2,5,7,12 & 24h Findings: Trospium was undetectable in all CSF samples. Trospium demonstrated no significant effects on total or delayed recall. Statskin, et al. Int J Clin Pract 2010;64:
21 Fesoterodine & Mirabegron 12-week R, DB, PC trial in vulnerable elderly subjects with urge UI 562 community-dwelling, >65 (mean 75) yrs., MMSE>20 Fesoterodine 4-8 mg/day (flexible dose) No deterioration in MMSE from baseline 2 reports of memory impairment with fesoterodine 1 withdrawal due to mild confusion (fesoterodine arm) Mirabegron DuBeau CE, et al. J Urol 2013;191: no data on cognitive function
22 Other Considerations Dose adjustment for renal function Mirabegron, tolterodine, trospium, solifenacin, fesoterodine Drug interactions CYP3A4 oxybutynin, tolterodine, darifenacin, fesoterodine, solifenacin CYP2D6 tolterodine, fesoterodine, darifenacin, mirabegron (inhibitor) Blood pressure mirabegron Do not take with food trospium Do not crush
23 Summary Medication Properties Control Trials Oxybutynin, oral Unfavorable EEG changes, negative control Oxybutynin, topical?? Tolterodine Unfavorable No EEG changes Trospium Favorable Undetectable CNS, no cog. Solifenacin Favorable Single dose, MCI Darifenacin Favorable NS cognitive changes Fesoterodine Fav/Unfav. No change in MMSE Mirabegron Favorable? No information 23
24 Which to Choose? All antimuscarinic OAB agents are superior to placebo None has been shown to be superior to the others Limited data on AChEI + OAB agents No clear winner Antimuscarinics lower doses, less risk Miragbegron intriguing choice, no data Monitor efficacy and safety. STOP if ineffective or suspected adverse effects. Try another agent
Overactive Bladder (OAB) Step Therapy Program
Overactive Bladder (OAB) Step Therapy Program Policy Number: 5.01.556 Last Review: 11/2018 Origination: 7/2013 Next Review: 11/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide
More informationOveractive Bladder (OAB) Step Therapy Program Policy Number: Last Review: Origination: Next Review: Policy When Policy Topic is covered:
Overactive Bladder (OAB) Step Therapy Program Policy Number: 5.01.556 Origination: 07/2013 Last Review: 11/2014 Next Review: 11/2015 Policy BCBSKC will provide coverage for brand name Overactive Bladder
More informationOveractive bladder (OAB) affects approximately 15% of the adult population. Diagnosis is based
Overactive bladder (OAB) affects approximately 15% of the adult population. Diagnosis is based upon a medical history, and includes a focused physical exam (abdominal, neurological, pelvic in females and
More informationPresentation Goals 4/14/2015. Pharmacology for Urinary Incontinence in Women. Medications Review anti muscarinic medications Focus on newer meds
Presentation Goals Pharmacology for Urinary Incontinence in Women Medications Review anti muscarinic medications Focus on newer meds Introduce beta adrenergic medications Current Concepts in Drug Therapy
More informationGeriatric Urinary Incontinence
Geriatric Urinary Incontinence Neil M. Resnick, MD Thomas Detre Professor of Medicine Chief, Division of Geriatric Medicine University of Pittsburgh/UPMC UI: The Problem Prevalence in elderly 33% Morbidity
More informationRational Pharmacotherapy for LUTS in Older People. Dr William Gibson MBChB MRCP
Rational Pharmacotherapy for LUTS in Older People Dr William Gibson MBChB MRCP Frailty Frailty = state of increased vulnerability resulting from agingassociated decline in reserve and function NOT synonymous
More informationInnovations in Childhood Incontinence: Neurogenic and Functional Bladder Disorders
TNe 10 Innovations in Childhood Incontinence: Neurogenic and Functional Bladder Disorders Stuart B. Bauer, MD President, ICCS Department of Urology Children s Hospital Boston Professor of Urology Harvard
More informationAnticholinergic medication use for female overactive bladder in the ambulatory setting in the United States.
Página 1 de 6 PubMed darifenacin vs solifenacin Display Settings:, Sorted by Recently Added Results: 5 1. Int Urogynecol J. 2013 Oct 25. [Epub ahead of print] Anticholinergic medication use for female
More informationDrugs for Overactive Bladder (OAB)
ril 2014 Drugs for Overactive Bladder (OAB) FINAL CONSOLIDATED COMPREHENSIVE RESEARCH PLAN July 2015 FINAL COMPREHENSIVE RESEARCH PLAN 2 A. Introduction The objective of the drug class review on drugs
More informationPrimary Care management of Overactive Bladder (OAB)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Primary Care management of Overactive Bladder (OAB) Prescribing Tips All medicines for OAB have similar dose-related efficacy. More than one agent (up
More informationSafety and Tolerability Profiles of Anticholinergic Agents Used for the Treatment of Overactive Bladder
REVIEW ARTICLE Drug Saf 2011; 34 (9): 733-754 0114-5916/11/0009-0733/$49.95/0 ª 2011 Adis Data Information BV. All rights reserved. Safety and Tolerability Profiles of Anticholinergic Agents Used for the
More informationThe Management of Overactive Bladder Syndrome with Antimuscarinic Drugs
The Management of Overactive Bladder Syndrome with Antimuscarinic Drugs Author Version Date Consultation Date of Ratification By JPG Shaista Hussain Joint Formulary Pharmacist V2 16.09.2014 Homerton University
More informationEvaluation and Treatment of Incontinence
Evaluation and Treatment of Incontinence Classification of Incontinence Failure to empty: Overflow incontinence Failure to store Stress Incontinence Urge Incontinence Physiology of voiding CNS Brain sends
More informationUrinary Incontinence for the Primary Care Provider
Urinary Incontinence for the Primary Care Provider Diana J Scott FNP-BC https://youtu.be/gmzaue1ojn4 1 Assessment of Urinary Incontinence Urge Stress Mixed Other overflow, postural, continuous, insensible,
More informationDr. Melissa Kagarise, PA C
Dr. Melissa Kagarise, PA C This program has been supported by an educational grant from Pfizer Pharmaceuticals PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of
More informationURGE MOTOR INCONTINENCE
URGE MOTOR INCONTINENCE URGE INCONTINENCE COMMONEST TYPE IN ELDERLY WOMEN Causes: 1 - Defects in CNS regulation Stroke Parkinson s disease Dementia (Alzheimer s and other types) Normopressure hydrocephalus
More informationManaging urinary incontinence in the elderly
Managing urinary incontinence in the elderly Cara Tannenbaum, MD, MSc Michel Saucier Endowed Chair Geriatric Pharmacology, Health & Aging Associate Professor of Medicine & Pharmacy, Université de Montréal
More informationCognitive Safety of Pharmacological Treatment of Urinary Incontinence: Will I make my patient worse?
Cognitive Safety of Pharmacological Treatment of Urinary Incontinence: Will I make my patient worse? Adrian Wagg, MB, FRCP, FHEA Division Director, Geriatric Medicine University of Alberta Zone Programme
More informationEvaluation & Management of Overactive Bladder
Evaluation & Management of Overactive Bladder Disclosures/Conflict of Interest/Bias I have no financial relationship with any of the companies that produce the products I m about to discuss I have no conflicts
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION MIRABEGRON (Myrbetriq Astellas Pharma Canada Inc.) Indication: Overactive Bladder Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that mirabegron be listed
More informationUrinary Incontinence in Women: Never an Acceptable Consequence of Aging
Urinary Incontinence in Women: Never an Acceptable Consequence of Aging Catherine A. Matthews, MD Associate Professor Chief, Urogynecology and Pelvic Reconstructive Surgery University of North Carolina,
More informationTITLE: Oxybutynin, Tolterodine, and Darifenacin: Review of Cognitive Adverse Events
TITLE: Oxybutynin, Tolterodine, and Darifenacin: Review of Cognitive Adverse Events DATE: 23 October 2009 CONTEXT AND POLICY ISSUES: Overactive bladder (OAB) affects men and women of varying ages 1 and
More informationCADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION PROPIVERINE HYDROCHLORIDE (Mictoryl/Mictoryl Pediatric Duchesnay Inc.) Indication: Overactive bladder This document was originally issued on April
More informationOveractive Bladder. Jennifer Mosher, WHNP-BC, CUNP Mercy Health Pelvic Medicine and Urogynecology Muskegon, Michigan
Overactive Bladder Jennifer Mosher, WHNP-BC, CUNP Mercy Health Pelvic Medicine and Urogynecology Muskegon, Michigan Speaker Disclosure I have nothing to disclose. 2 Learning Objectives Define OAB Identify
More informationTreatment for Overactive Bladder
ril 2014 Treatment for Overactive Bladder Stakeholder Review STAKEHOLDER REVIEW 2 GENERAL Comment: ODPRN should consider more prominently identifying one of the key limitations in their assessment and
More informationTREATMENT OF OVERACTIVE BLADDER IN ADULTS FUGA 2016 KGH
TREATMENT OF OVERACTIVE BLADDER IN ADULTS FUGA 2016 KGH CONTENTS Overactive bladder (OAB) Treatment of OAB Beta-3 adrenoceptor agonist (Betmiga ) - Panacea? LASER treatment - a flash in the pan or the
More informationNICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.
bring together all NICE guidance, quality standards and other NICE information on a specific topic. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published.
More informationDiagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline.
Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. TARGET POPULATION Eligibility Decidable (Y or N) Inclusion Criterion non-neurogenic OAB Exclusion Criterion
More informationDrugs for the overactive bladder: are there differences in persistence and compliance?
Editorial Drugs for the overactive bladder: are there differences in persistence and compliance? Karl-Erik Andersson 1,2 1 Institute for Regenerative Medicine, Wake Forest University School of Medicine,
More informationSELECTED POSTER PRESENTATIONS
SELECTED POSTER PRESENTATIONS The following summaries are based on posters presented at the American Urogynecological Society 2004 Scientific Meeting, held July 29-31, 2004, in San Diego, California. CENTRAL
More informationManagement of OAB. Lynsey McHugh. Consultant Urological Surgeon. Lancashire Teaching Hospitals
Management of OAB Lynsey McHugh Consultant Urological Surgeon Lancashire Teaching Hospitals Summary Physiology Epidemiology Definitions NICE guidelines Evaluation Conservative management Medical management
More informationril 2014 FINAL CONSOLIDATED REPORT MARCH 2016 Treatment of Overactive Bladder
ril 2014 FINAL CONSOLIDATED REPORT MARCH 2016 Treatment of Overactive Bladder FINAL REPORT 2 The (ODPRN) is funded to conduct drug class reviews as part of an initiative to modernize the public drug formulary
More informationReport on New Patented Drugs - Vesicare
Report on New Patented Drugs - Vesicare Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the Board's Excessive
More informationTHE OVER-ACTIVE BLADDER (OAB)
THE OVER-ACTIVE BLADDER (OAB) Passage of urine is caused by the bladder muscle contracting coordinated with the relaxation of the sphincter muscles, which is controlled by higher centers in the central
More informationOveractive Bladder. When to see a doctor. Normal bladder function
Overactive Bladder Overactive bladder is a problem with bladder-storage function that causes a sudden urge to urinate. The urge may be difficult to stop, and overactive bladder may lead to the involuntary
More informationUNC Cancer Epidemiology Seminar: Cancer Risk in New Users of Overactive Bladder Drugs
February 19, 2016 UNC Cancer Epidemiology Seminar: Cancer Risk in New Users of Overactive Bladder Drugs James A. Kaye, MD, DrPH Senior Director, Epidemiology, RTI Health Solutions Collaborators: Andrea
More informationPharmacologic management of overactive bladder
REVIEW Pharmacologic management of overactive bladder Sum Lam 1,2 lga Hilas 1,3 1 St. John s University, College of Pharmacy and Allied Health Professions, Department of Clinical Pharmacy Practice, Queens,
More informationUrinary Incontinence. Lee A. Jennings, MD, MSHS. Assistant Professor Reynolds Department of Geriatrics University of Oklahoma Health Sciences Center
Urinary Incontinence Lee A. Jennings, MD, MSHS Assistant Professor Reynolds Department of Geriatrics University of Oklahoma Health Sciences Center Slides adapted from Alison Moore, MD, MPH University of
More informationUrinary Incontinence: The Neglected Geriatric Syndrome. Dr. Martha Spencer, MD, FRCPC Providence Health Care Clinical Instructor, UBC
Urinary Incontinence: The Neglected Geriatric Syndrome Dr. Martha Spencer, MD, FRCPC Providence Health Care Clinical Instructor, UBC Poll Question 1: Urinary incontinence is an expected consequence of
More informationAppendix 2 Drug Information
Appendix 2 Drug Information Chemical Name: baclofen (bak-loe-fen) Brand Name: Lioresal (U.S. and Canada) Description: Baclofen acts on the central nervous system to relieve spasms, cramping, and tightness
More informationManagement of Urinary Incontinence George A. DeMaagd, PharmD, BCPS; and Timothy C. Davenport, MD
George A. DeMaagd, PharmD, BCPS; and Timothy C. Davenport, MD DISEASE OVERVIEW Urinary incontinence (UI) may be defined as any involuntary or abnormal urine loss. UI is characterized by lower urinary tract
More informationOVERACTIVE BLADDER IN THE ELDERLY PATIENT
Program Name: OVERACTIVE BLADDER IN THE ELDERLY PATIENT Planning Committee: John Papastergiou, BScPhm Denise Gélinas, B.Pharm, MBA Surinder Gill, BScPhm Accrediation Information: This version of the program
More informationParkinson s Disease and Multiple System Atrophy
Parkinson s Disease and Multiple System Atrophy Jalesh N. Panicker MD, FRCP Department of Uro-Neurology National Hospital for Neurology and Neurosurgery and UCL Institute of Neurology Queen Square, London
More informationThe International Urogynecological Association and the
ORIGINAL RESEARCH Comparing Direct Medical Costs of OnabotulinumtoxinA With Other Common Overactive Bladder Interventions Alon Yehoshua, PharmD, MS; Brian P. Murray, MD; Sandip P. Vasavada, MD; and Peter
More informationOveractive Bladder Syndrome
Overactive Bladder Syndrome behavioural modifications to pharmacological and surgical treatments Dr Jos Jayarajan Urologist Austin Health, Eastern Health Warringal Private, Northpark Private, Epworth Overactive
More informationAn Overview of Overactive Bladder and Its Pharmacological Management with a Focus on Anticholinergic Drugs
An Overview of Overactive Bladder and Its Pharmacological Management with a Focus on Anticholinergic Drugs George DeMaagd, PharmD, BCPS, and Jeffrey D. Geibig, PharmD Educational Objectives After reviewing
More informationDRUG FORECAST. Select Conditions of the Lower Urinary Tract
Transdermal Oxybutynin: Novel Drug Delivery for Overactive Bladder Vitalina Rozenfeld, PharmD, BCPS, Stanley Zaslau, MD, Kathleen New Geissel, PharmD, David Lucas, PhD, and Lili Babazadeh, PharmD INTRODUCTION
More informationDrug Class Review Agents for Overactive Bladder
Drug Class Review Agents for Overactive Bladder Final Update 4 Report March 2009 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationDr Jonathan Evans Paediatric Nephrologist
How do I manage a patient with intractable daytime wetting: Dr Jonathan Evans Paediatric Nephrologist Of 107 children aged 11-12 with day-wetting 91 (85%) were dry at 15-16 yr Swithinbank et al BJU 1998
More informationFDA Briefing Document for Nonprescription Drugs Advisory Committee
FDA Briefing Document for Nonprescription Drugs Advisory Committee Oxybutynin Transdermal System NDA 202211 Proposed Indication: Treats overactive bladder in women Topic: Partial Rx-to-OTC switch for oxybutynin
More informationThe Effects of AntimuscarinicTreatments in Overactive Bladder: A Systematic Review and Meta-Analysis
European Urology European Urology 48 (2005) 5 26 ReviewöOveractive Bladder The Effects of AntimuscarinicTreatments in Overactive Bladder: A Systematic Review and Meta-Analysis Christopher Chapple a, *,
More informationObjectives. Prevalence of Urinary Incontinence URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS
URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS Lisa S Pair, MSN, CRNP Division of Urogynecology and Pelvic Reconstructive Surgery Department of Obstetrics and Gynecology University of Alabama
More informationTreatment of OAB in postmenopause. Držislav Kalafatić Department Obstetrics and Gynecology School of Medicine, University of Zagreb
Treatment of OAB in postmenopause Držislav Kalafatić Department Obstetrics and Gynecology School of Medicine, University of Zagreb Spectrum of overactive bladder Urinary urgency usually accompanied by
More informationTaking Control of your Bladder, or. Don't make me laugh when laughter isn't the best medicine: a discussion on urinary incontinence
Taking Control of your Bladder, or Don't make me laugh when laughter isn't the best medicine: a discussion on urinary incontinence Brett Vassallo, MD, FACOG, FAC Female Pelvic Medicine and Reconstructive
More informationOveractive Bladder beyond antimuscarinics
Overactive Bladder beyond antimuscarinics Marcus Drake Bristol Urological Institute Conflicts of interest; Allergan, AMS, Astellas, Ferring, Pfizer Getting the diagnosis right Improving treatment Improving
More informationReport on New Patented Drugs Enablex
Report on New Patented Drugs Enablex Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the PMPRB s Excessive
More informationTechnology appraisal guidance Published: 26 June 2013 nice.org.uk/guidance/ta290
Mirabegron for treating symptoms of overactive bladder Technology appraisal guidance Published: 26 June 2013 nice.org.uk/guidance/ta290 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationVictoria Sharp, MD, MBA, FAAFP. Clinical Professor of Urology and Family Medicine
Victoria Sharp, MD, MBA, FAAFP Clinical Professor of Urology and Family Medicine Victoria Sharp, MD, MBA, FAAFP Market Chief Medial Officer AmeriHealth Caritas Family of Companies Office phone: (515) 330-3740
More informationDOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. Uniform Formulary Review Process Under 10 U.S.C. 1074g, as implemented by 32
More informationOveractive bladder affects 33 million adults in the United
Overactive Bladder: Treatment Options in Primary Care Medicine David O. Sussman, DO Overactive bladder is a highly prevalent condition, affecting approximately 33 million adults in the United States. Despite
More informationUrinary Incontinence. Alison A Moore, MD, FACP
Urinary Incontinence Alison A Moore, MD, FACP Professor of Medicine/Geriatric Medicine David Geffen School of Medicine at UCLA Department of Medicine, Division of Geriatrics Urinary Incontinence (UI) Involuntary
More informationManagement, Evaluation, and Treatment of Overactive Bladder and Urinary Incontinence
Management, Evaluation, and Treatment of Overactive Bladder and Urinary Incontinence Arthur Mourtzinos, MD, MBA Co-Vice Chair, Institute of Urology Director, Continence Center Assistant Professor of Urology,
More informationAccording to the INDICATIONS AND USAGE section of its FDA-approved product labeling (PI):
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 TRANSMITTED BY FACSIMILE Karen L. Walles, M.S. Assistant Director, Regulatory Affairs 3
More informationOVERACTIVE BLADDER (OAB)
OVERACTIVE BLADDER (OAB) Ms Taryn Hallam Alana Health Care for Women Women s Health Training Associates OVERACTIVE BLADDER The most misdiagnosed and misunderstood of all the urinary disorders. Problem???
More informationDisclosures. Geriatric Incontinence and Voiding Dysfunction. Agenda. Agenda. UI: a Geriatric Syndrome. Geriatric Syndromes 9/7/2018.
Disclosures Geriatric Incontinence and Voiding Dysfunction None Shachi Tyagi MD, MS Assistant Professor Division of Geriatric Medicine University of Pittsburgh Medical Center UI: a Geriatric Syndrome Geriatric
More informationUrinary incontinence and pelvic organ prolapse in women: management
National Institute for Health and Care Excellence Draft for consultation Urinary incontinence and pelvic organ prolapse in women: management [C] Evidence review on the risks to cognitive function for women
More informationUrinary Incontinence and Overactive Bladder Update NICE Guidelines on UI for women - GP Perspectives
Urinary Incontinence and Overactive Bladder Update NICE Guidelines on UI for women - GP Perspectives Arun Sahai PhD, FRCS (Urol) Consultant Urological Surgeon & Honorary Senior Lecturer Guy s Hospital
More informationDrug Class Review on Urinary Incontinence Drugs
Drug Class Review on Urinary Incontinence Drugs FINAL REPORT February 2003 Marian S. McDonagh, PharmD Produced by Oregon Evidence-based Practice Center Oregon Health & Science University 3181 SW Sam Jackson
More informationEtiology, risk factors, and management overactive bladder : Review
International Journal of Scientific & Engineering Research Volume 9, Issue 1, January-2018 1152 Etiology, risk factors, and management overactive bladder : Review Saud Mohammed Saud Aleisa, Abdulrahman
More informationDarifenacin: first M3 receptor antagonist for overactive bladder
Darifenacin: first M3 receptor antagonist for overactive bladder Steve Chaplin MSc, MRPharmS and Christopher Chapple BSc, MD, FRCS(Urol) PRODUCT PROFILE Proprietary name: Emselex Constituents: darifenacin
More informationSafe Prescribing in Dementia
Safe Prescribing in Dementia Dr Daniel Harwood Consultant Psychiatrist and Clinical Director, London Strategic Clinical Network Gurdeep Kaur Major Rapid Access Team Senior Pharmacist, Camden CNWL NHS Trust
More informationDOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. Uniform Formulary Review Process Under 10 U.S.C. 1074g, as implemented by 32
More informationOffice based non-oncology urology trials Richard W. Casey, MD, 1 Jack Barkin, MD 2
Office based non-oncology urology trials Richard W. Casey, MD, 1 Jack Barkin, MD 2 1 The Male Health Centre, Oakville, Ontario, Canada 2 Humber River Regional Hospital, University of Toronto, Toronto,
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Urinary incontinence in women: the management of urinary incontinence in women 1.1 Short title Urinary incontinence in women
More informationI. Uniform Formulary Review Process
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. Uniform Formulary Review Process Under 10 U.S.C. 1074g, as implemented by 32
More informationSubjective Measures of Efficacy: Quality of Life, Patient Satisfaction and Patient-Oriented Goals the Search for Value
european urology supplements 6 (2007) 438 443 available at www.sciencedirect.com journal homepage: www.europeanurology.com Subjective Measures of Efficacy: Quality of Life, Patient Satisfaction and Patient-Oriented
More informationSTEP THERAPY IN MEDICARE PART D
STEP THERAPY IN MEDICARE PART D Sarkis Kavarian, PharmD Candidate 15 Preceptor Dr. Craig Stern Pro Pharma Pharmaceutical Consultants, Inc. May 1 st, 2015 Objectives Why is this important? Medicare Part
More informationSome people experience occasional, minor leaks of urine. Others wet their clothes frequently.
Urinary Incontinence Urinary incontinence the loss of bladder control is a common and often embarrassing problem. The severity ranges from occasionally leaking urine when you cough or sneeze to having
More informationDrug Class Review on Overactive Bladder Drugs
Drug Class Review on Overactive Bladder Drugs Preliminary Scan Report #1 February 2014 Last Summary Review (June 2013) The Agency for Healthcare Research and Quality has not yet seen or approved this report
More informationNEW DEVELOPMENTS IN HYPERTENSION. Clinical Issues in Geriatrics for Primary Care Practice
Clinical Issues in Geriatrics for Primary Care Practice Eliseo J. Pérez-Stable MD Professor of Medicine DGIM, Department of Medicine April 7, 2015 Declaration of full disclosure: No conflict of interest
More informationSupplement. Updated Literature Search for Pharmacologic Treatments for Urgency UI
Supplement. Updated Literature Search for Pharmacologic Treatments for Urgency UI Authors: Tatyana A. Shamliyan, MD, MS Senior Director, Evidence-Based Medicine Quality Assurance Elsevier 1600 JFK Blvd,
More informationThe International Continence Society
REPORTS Safety and Tolerability of Tolterodine for the Treatment of Overactive Bladder in Adults Richard G. Roberts, MD, JD; Alan D. Garely, MD; and Tamara Bavendam, MD Abstract This article evaluates
More informationSenioRx Care Perspective
CT-ASCP's SenioRx Care Perspective Inside: UCONN Student Chapter Update Page 2 New Choices for an Old Problem: Pages 3-5 Urinary Incontinence Medications in Overactive Bladder Notes n Votes August 2015
More informationNEW DEVELOPMENTS IN HYPERTENSION
Common Problems in Older Women Using Geriatric Principles in Every Day Practice Eliseo J. Pérez-Stable MD Professor of Medicine DGIM, Department of Medicine July 3, 2013 Declaration of full disclosure:
More informationCase Consults in Overactive Bladder: An Individualized Approach to Management 12:45 p.m. 2:00 p.m. December 2, 2008 Atlanta, GA
Case Consults in Overactive Bladder: An Individualized Approach to Management 12:45 p.m. 2:00 p.m. December 2, 2008 Atlanta, GA Education Partner: Session 4: Case Consults in Overactive Bladder: An Individualized
More informationOveractive Bladder (OAB) and Quality of Life
Overactive Bladder (OAB) and Quality of Life Dr. Byron Wong MBBS (Sydney), FRCSEd, FRCSEd (Urol), FCSHK, FHKAM (Surgery) Specialist in Urology Central Urology Clinic Hong Kong Continence Society Annual
More informationUrogynecology Office. Can You Hold? An Update on the Treatment of OAB. Can You Hold? Urogynecology Office
Urogynecology Office Urogynecology Office Can You Hold? An Update on the Treatment of OAB Can You Hold? Karen Noblett, MD Professor and Chair Department of OB/GYN University of California, Riverside Disclosures
More informationOveractive Bladder: Identifying Patients at Risk, Implementing New Strategies
Overactive Bladder: Identifying Patients at Risk, Implementing New Learning Objectives Identify patients with OAB risk factors in order to proactively initiate a discussion about bladder symptoms and establish
More information1:10 PM II. CONSENT AGENDA TOPICS T. Klein (Chair)
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program OHA Division of Medical Assistance Programs 500 Summer Street NE, E35; Salem, OR 97301-1079 Phone 503-947-5220
More informationLiterature Scan: Alzheimer s Drugs
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationEfficacy and Safety of Propiverine and Solifenacin for the Treatment of Female Patients with Overactive Bladder: A Crossover Study
LUTS () 3, 36 4 ORIGINAL ARTICLE Efficacy and Safety of Propiverine and Solifenacin for the Treatment of Female Patients with Overactive Bladder: A Crossover Study Naoki WADA, Masaki WATANABE, Masafumi
More informationUniform Formulary Beneficiary Advisory Panel Handout February 2006
Uniform Formulary Beneficiary Advisory Panel Handout February 2006 PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinicaleffectiveness
More informationCare of the Geriatric Patient: Selected topics
Care of the Geriatric Patient: Selected topics Primary Care Days April 9, 2013 Sarah M McGee MD, MPH UMassMemorial Medical Center Disclosures I have no financial relationships with any commercial interests
More informationMuscarinic receptor antagonists for overactive bladder
Great drug classes ANTIMUSCARINIC DRUGS FOR OAB From time to time we publish a full review of drugs that are available for the treatment of common conditions. In this issue, the review is written by two
More informationPriorities Forum Statement GUIDANCE
Priorities Forum Statement Number 61 Subject The management of female incontinence Date of decision May 2016 Date refreshed May 2017 Date of review May 2019 Introduction: GUIDANCE Urinary incontinence
More informationRECENT ADVANCES IN THE MANAGEMENT OF URINARY INCONTINENCE
RECENT ADVANCES IN THE MANAGEMENT OF URINARY INCONTINENCE SAAD JUMA, MD INCONTINENCE RESEARCH INSTITUTE ENCINITAS, CA AUA STRESS URINARY INCONTINENCE GUIDELINE UPDATE INDEX PATIENTS The otherwise healthy
More informationEfficacy and Adverse Effects of Solifenacin in the Treatment of Lower Urinary Tract Symptoms in Patients With Overactive Bladder
Urol Sci 21;21(1):38 43 ORIGINAL ARTICLE Efficacy and Adverse Effects of Solifenacin in the Treatment of Lower Urinary Tract Symptoms in Patients With Overactive Bladder Yih-Chou Chen, Chia-Yen Chen, Hann-Chorng
More informationManagement of urinary incontinence in older people Shashi Gadgil BSc, MRCP and Adrian Wagg FRCP
Management of urinary incontinence in older people Shashi Gadgil BSc, MRCP and Adrian Wagg FRCP Prevalence (%) 40 35 30 25 20 15 10 5 Our series Prescribing in older people gives practical advice for successful
More informationOAB Treatment Guidelines
OAB Treatment Guidelines This Practice Aid has been provided as a quick reference to help learners apply the information to their daily practice and care of patients. It is part of the activity Overcoming
More informationBladder antimuscarinics use in the veterans affairs community living centers: description of medication use and evaluation of risks and benefits
University of Iowa Iowa Research Online Theses and Dissertations 2012 Bladder antimuscarinics use in the veterans affairs community living centers: description of medication use and evaluation of risks
More information